AlloSource Announces Milestone In Production Of Bioengineered Blood Vessels For Humacyte’s Vascular Access Phase III Clinical Trial
Centennial, Colo. – September 12, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue and cellular allografts for use in surgical procedures to advance patient healing, today announced a major milestone in its partnership with Humacyte. AlloSource…
September 12, 2017Press ReleasesFood and Drug Administration (FDA),HUMACYL®,hemodialysis,Humacyte,vascular access
AlloSource Distributes First Bioengineered Blood Vessels For Humacyte Phase III Clinical Trial
Centennial, Colo. — May 23, 2016 — AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced the distribution of investigational bioengineered blood…
May 23, 2016Press ReleasesFood and Drug Administration (FDA),Humacyte,vascular access,Clinical Trial,hemodialysis,AlloSource